TABLE 3.
Clinical characteristics of patients with vancomycin-associated SJS and Linezolid-associated SJS collected from the FAERS database (January 2004 to July 2021).
| Characteristics | Reports (N, %) | |
|---|---|---|
| Vancomycin | Linezolid | |
| Patient age (year) | ||
| <18 | 17 (6.16) | 1 (1.59) |
| 18–44 | 41 (14.86) | 2 (3.17) |
| 45–64 | 87 (31.52) | 23 (36.51) |
| 65–74 | 55 (19.93) | 17 (26.98) |
| >74 | 41 (14.86) | 4 (6.35) |
| Unknown | 35 (12.68) | 16 (25.40) |
| Patient gender | ||
| Female | 121 (43.84) | 29 (46.03) |
| Male | 136 (49.28) | 28 (44.44) |
| Unknown | 19 (0.36) | 6 (1.59) |
| Area | ||
| Africa | 0 (0.00) | 0 (0.00) |
| Asia | 26 (9.42) | 8 (12.70) |
| Europe | 90 (32.61) | 26 (41.27) |
| Oceania | 0 (0.00) | 0 (0.00) |
| North America | 130 (47.10) | 26 (41.27) |
| South America | 6 (2.17) | 1 (1.59) |
| Unknown | 24 (8.70) | 2 (3.17) |
| Reporters | ||
| Consumer | 7 (2.54) | 3 (4.76) |
| Lawyer | 11 (3.99) | 0 (0.00) |
| Pharmacist | 77 (27.90) | 19 (30.16) |
| Physician | 68 (24.64) | 10 (15.87) |
| Other health-professional | 66 (23.91) | 21 (33.33) |
| Unknown | 47 (17.03) | 10 (15.87) |
| Outcome event | ||
| Death | 93 (33.70) | 25 (39.68) |
| Disability | 18 (6.52) | 3 (4.76) |
| Hospitalization-Initial or Prolonged | 144 (52.17) | 28 (44.44) |
| Life-Threatening | 59 (21.38) | 17 (26.98) |
| Other Serious (Important Medical Event) | 122 (44.20) | 35 (55.56) |
| Required Intervention to Prevent Permanent Impairment/Damage | 17 (6.16) | 1 (1.59) |
FAERS, FDA, adverse event reporting system.